Obesity Medicine

Despite its limitations for use in other populations, a high BMI proved a very good predictor of dangerous fat mass index in youth aged 8 to 19 years in this study.

The interactive tool provides clinicians and patients a real-time look at GLP-1RA availability.

Shagun Bindlish, MD, discusses the complex interplay between obesity and mental health conditions and how sex is a potential moderating factor.

DDW 2024. Offspring with both parents with overweight had a nearly 3-fold increased risk of MASLD in young adulthood, according to new data.

In the phase 1b trial, treatment with once-weekly subcutaneous CT-388 led to a statistically significant mean placebo-adjusted weight loss of nearly 20%.

Your daily dose of the clinical news you may have missed.

Analyses of the SELECT trial found mean weight loss of 10.2% sustained for 4 years and comparable CV benefit with weight loss greater or less than 5%, or even weight gain.

Results also showed that older adults, men, and Black adults face an increased risk of advanced stages of CKM syndrome.

Your daily dose of the clinical news you may have missed.

Naim Alkhouri, MD, a transplant hepatologist and a resmetirom investigator, talks here about the life-changing impact the drug will have for all touched by MASH.

Primary care is where early detection and treatment of liver disease should begin and as Dr Alkhouri highlights here, all the right tools are already at hand.

The national study on the true prevalence of metabolic dysfunction-associated liver disease is essential to screening, prevention, and treatment efforts, says AFL CEO Stiehl.

Adults receiving semaglutide for the first time achieved weight loss of 14.3% at 12 months vs 10.6% among those who had previously taken a different antiobesity drug.

Your daily dose of the clinical news you may have missed.

Among persons with COPD whose BMI decreased over a 4-year follow-up, mortality risk rose 70% compared with those whose BMI remained the same, researchers reported.

With the rise in demand for newer antiobesity medications, clinicians may face more questions from patients. Here, a primer on the drawbacks and benefits to keep in mind.

Tirzepatide reduced OSA symptoms and body weight in study participants with severe OSA and obesity, regardless of use of positive airway pressure therapy.

Results of a recent study support the importance of lifestyle interventions to reduce the burden of breathlessness in middle-aged adults.

Your daily dose of the clinical news you may have missed.

Monu Khanna, MD, discusses challenges in managing pain in patients with obesity, effective pharmacological and nonpharmacological therapies, and more.

LPCN 2401, a combination anabolic androgen receptor agonist and α-tocopherol, decreased fat mass by 6.7% and increased lean mass by 4.4% over 36 weeks, said Lipocine, Inc.

Shagun Bindlish, MD, board member of the American Diabetes Association, details available options for treating venous disease in patients with obesity.

ACC.24: Results of STEP HFpEF DM showed significant improvement in quality of life measures among adults with obesity-related HFpEF and type 2 diabetes.

ACC.2024: Two abstracts presented during the ACC Scientific Sessions indicate cardiologists are very hesitant to prescribe medical therapy for obesity.

The once daily tablet, VK2375, is headed to a phase 2 trial later this year and is an oral version of Viking's investigational injectable GLP-1/GIP mimetic currently in phase 2.

CMS says Medicare Part D plans will cover semaglutide for individuals with overweight/obesity who have preexisting CVD, a first after 40 years of legal prohibition.

Shagun Bindlish, MD, board member of the American Diabetes Association, discusses a recent clinical practice statement she coauthored published in the journal Obesity Pillars.

The inaugural digital issue of Patient Care focuses on the antiobesity and type 2 diabetes medications, semaglutide and tirzepatide.

The label expansion for semaglutide, based on the SELECT trial, includes data showing reduced risk of CV death of 15% and of death from any cause of 19%.